JP2007531764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531764A5 JP2007531764A5 JP2007506541A JP2007506541A JP2007531764A5 JP 2007531764 A5 JP2007531764 A5 JP 2007531764A5 JP 2007506541 A JP2007506541 A JP 2007506541A JP 2007506541 A JP2007506541 A JP 2007506541A JP 2007531764 A5 JP2007531764 A5 JP 2007531764A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- alkyl
- hydroxy
- aryl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- -1 hydroxy, hydroxy Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ALPXOAMTGWMAJH-UHFFFAOYSA-N 5-[4-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl]ethoxy]phenyl]-2,3-dihydro-1,3,4-oxadiazole Chemical compound CC1=C(N=C(S1)C1=CC=C(C=C1)C(F)(F)F)CCOC1=CC=C(C=C1)C1=NNCO1 ALPXOAMTGWMAJH-UHFFFAOYSA-N 0.000 claims 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 108010015181 PPAR delta Proteins 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55842004P | 2004-04-01 | 2004-04-01 | |
| US60/558,420 | 2004-04-01 | ||
| PCT/US2005/010855 WO2005097763A2 (en) | 2004-04-01 | 2005-03-30 | 1,3,4-oxadiazol-2-ones as ppar delta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007531764A JP2007531764A (ja) | 2007-11-08 |
| JP2007531764A5 true JP2007531764A5 (https=) | 2008-04-17 |
| JP4813461B2 JP4813461B2 (ja) | 2011-11-09 |
Family
ID=34972960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506541A Expired - Fee Related JP4813461B2 (ja) | 2004-04-01 | 2005-03-30 | Ｐｐａｒデルタモジュレーターとしての１，３，４−オキサジアゾール−２−オン、および、それらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7638539B2 (https=) |
| EP (1) | EP1781648A2 (https=) |
| JP (1) | JP4813461B2 (https=) |
| CN (1) | CN1956984B (https=) |
| AU (1) | AU2005230838A1 (https=) |
| BR (1) | BRPI0508180A (https=) |
| CA (1) | CA2561230A1 (https=) |
| IL (1) | IL178166A0 (https=) |
| MA (1) | MA28563B1 (https=) |
| NO (1) | NO20064951L (https=) |
| NZ (1) | NZ549823A (https=) |
| RU (1) | RU2365589C2 (https=) |
| SG (1) | SG151336A1 (https=) |
| WO (1) | WO2005097763A2 (https=) |
| ZA (1) | ZA200607852B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ550857A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
| AU2005230838A1 (en) * | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as PPAR delta |
| DE602005024384D1 (de) | 2004-05-05 | 2010-12-09 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
| CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
| US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| BRPI1107312B1 (pt) * | 2011-11-25 | 2021-09-08 | Universidade Federal De Santa Catarina | Composto de acil-hidrazona |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| KR101715127B1 (ko) * | 2015-10-30 | 2017-03-15 | 한국과학기술연구원 | 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체 |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| CN114195777B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪（上海）医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
| CN114195786B (zh) * | 2020-09-18 | 2023-08-22 | 凯思凯迪（上海）医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4895953A (en) * | 1987-09-30 | 1990-01-23 | American Home Products Corporation | 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
| US4826990A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| ES2277842T3 (es) * | 1999-06-18 | 2007-08-01 | MERCK & CO., INC. | Derivados de ariltiazolidindiona y de ariloxazolidindiona. |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| US6506781B1 (en) * | 1999-09-08 | 2003-01-14 | Smithkline Beecham Corporation | Oxazole PPAR antagonist |
| WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
| JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| AU2005230838A1 (en) * | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as PPAR delta |
| NZ550857A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
-
2005
- 2005-03-30 AU AU2005230838A patent/AU2005230838A1/en not_active Abandoned
- 2005-03-30 JP JP2007506541A patent/JP4813461B2/ja not_active Expired - Fee Related
- 2005-03-30 RU RU2006138494/04A patent/RU2365589C2/ru not_active IP Right Cessation
- 2005-03-30 EP EP05767047A patent/EP1781648A2/en not_active Withdrawn
- 2005-03-30 WO PCT/US2005/010855 patent/WO2005097763A2/en not_active Ceased
- 2005-03-30 CN CN200580017003.5A patent/CN1956984B/zh not_active Expired - Fee Related
- 2005-03-30 CA CA002561230A patent/CA2561230A1/en not_active Abandoned
- 2005-03-30 BR BRPI0508180-7A patent/BRPI0508180A/pt not_active IP Right Cessation
- 2005-03-30 NZ NZ549823A patent/NZ549823A/en unknown
- 2005-03-30 SG SG200902266-6A patent/SG151336A1/en unknown
-
2006
- 2006-09-18 IL IL178166A patent/IL178166A0/en unknown
- 2006-09-19 ZA ZA200607852A patent/ZA200607852B/en unknown
- 2006-09-27 US US11/535,764 patent/US7638539B2/en not_active Expired - Fee Related
- 2006-10-30 NO NO20064951A patent/NO20064951L/no not_active Application Discontinuation
- 2006-10-31 MA MA29429A patent/MA28563B1/fr unknown
-
2009
- 2009-07-20 US US12/505,881 patent/US7872032B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007531764A5 (https=) | ||
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| JP2010529203A5 (https=) | ||
| JP5261383B2 (ja) | ヒトプロテインチロシンホスファターゼ阻害剤および使用法 | |
| JP2004534035A5 (https=) | ||
| RU2006138494A (ru) | 1, 3, 4-оксадиазол-2-оны в качестве модуляторов ppar-ельта и их применение | |
| JP2005502600A5 (https=) | ||
| JP2009530281A5 (https=) | ||
| JP2007502264A5 (https=) | ||
| JP2004532266A5 (https=) | ||
| RU2003112691A (ru) | Бензамидные соединения в качестве ингибиторов секреции аро в | |
| JP2005508318A5 (https=) | ||
| ZA200100983B (en) | Substituted oxazoles and thiazoles derivatives as hPPAR gamma and hPPAR alpha activators. | |
| RU2019121871A (ru) | Новые производные фенилпропионовой кислоты и их применение | |
| JP2016500063A5 (https=) | ||
| RU2015141278A (ru) | Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента | |
| ZA200308352B (en) | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors. | |
| JP2009542659A5 (https=) | ||
| NZ598548A (en) | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | |
| JP2003523336A5 (https=) | ||
| JP2004518702A5 (https=) | ||
| RU2002118339A (ru) | Транс-олефиновые активаторы глюкокиназы | |
| JP2004517100A5 (https=) | ||
| JP2009531280A5 (https=) | ||
| JP2007531763A5 (https=) |